StreetInsider.com News Articles

Avicanna Transitions US Listing to OTCQB

Fri, 16 Oct 2026 17:30:00 -0400

TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026.

About Avicanna:

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in

Avicanna Transitions US Listing to OTCQB

Fri, 16 Oct 2026 17:30:00 -0400

About Avicanna:

Avicanna Transitions US Listing to OTCQB

Fri, 16 Oct 2026 17:30:00 -0400

About Avicanna:

Avicanna Transitions US Listing to OTCQB

Fri, 16 Oct 2026 17:30:00 -0400

About Avicanna:

Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026

Tue, 15 Sep 2026 07:30:00 -0400

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.

Avicanna Participates in Virtual Conference OTC Markets Press Release Sept 26 VirtualInvestorConferences.com on September 17th, 2026.

Avicanna Participates in Virtual Conference OTC Markets Press Release Sept 26 TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks.

The program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels and is intended to support hospitals, specialty clinics, multidisciplinary healthcare networks, insurers and other healthcare organizations seeking to incorporate structured medical cannabis pathways into their existing models of care. The Program

Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

Wed, 09 Sep 2026 07:30:00 -0400

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks.

Avicanna closes $500,000 private placement with pharma investor

Wed, 19 Aug 2026 07:30:19 -0400

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.

The offering consisted of 3,333,334 units priced at $0.15 per unit. Each unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, expiring Aug. 18, 2029.

The investor is Michael W. Porter, Founder and Managing Partner at PG Equity Group I, LLC. Porter previously co-founded Covis Pharma Group, where he served as CEO. He currently serves as Executive Chairman of AltaNova

Avicanna closes $500,000 private placement with pharma investor

Wed, 19 Aug 2026 07:30:19 -0400

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.

Avicanna closes $500,000 private placement with pharma investor

Wed, 19 Aug 2026 07:30:19 -0400

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.

Avicanna closes $500,000 private placement with pharma investor

Wed, 19 Aug 2026 07:30:19 -0400

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.

Avicanna Announces Closing of Strategic Non-Brokered Private Placement